4.65 DESTINY BREAST 04 - A complex trial to deconstruct

My take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

Om Podcasten

A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California, San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com.